A Robert W. Baird and Co. analyst predicts a strong year for shares of four medical device makers, saying that in 2010, investors may be more willing to take a risk on companies in high-growth fields. Lawrence Neibor upgraded shares of Cyberonics, Edwards Lifesciences , Thoratec Inc., and Volcano Corp. to "Outperform" from "Neutral" and he downgraded Boston Scientific Corp. to "Neutral" from "Outperform" because most of its revenue comes from sales of drug-coated stents and cardiac rhythm products, two markets he said are well developed and not growing very fast. Investors shrugged off part of the report; Boston Scientific stock rose 8 cents to $9.08.